Skip to Main Navigation
Skip to Page Content
COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/8933

Target Organs and Levels of Evidence for TR-368

Toxicology and Carcinogenesis Studies of Nalidixic Acid (CASRN 389-08-2) in F344/N Rats and B6C3F1 Mice (Feed Studies)

Chemical (Study Title)
CASRN
Peer Review Date Route/Exposure Levels Study Laboratory
Nalidixic acid
389-08-2
03/13/1989 Dosed-Feed
R&M: 0, 2000, 4000 PPM/50 PER GROUP
Physiological Research Laboratory

Levels of Evidence

Male Rats: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Preputial Gland: ADENOMA 2/49 10/49 10/47, PAPILLOMA 1/49 0/49 0/47, OR CARCINOMA 0/49 10/49 12/47 COMBINED 3/49 19/49 20/47
Female Rats: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Clitoral Gland: ADENOMA 4/46 10/46 11/47, PAPILLOMA 0/46 1/46 0/47, OR CARCINOMA 1/46 4/46 5/47 COMBINED 5/46 15/46 16/47
Male Mice: Equivocal Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Subcutaneous Tissue: FIBROMA 1/50 3/50 3/50 OR FIBROSARCOMA 4/50 6/50 11/50 COMBINED 5/50 9/50 14/50
Female Mice: No Evidence